CT
Canntab Therapeutics Limited
CTABF · OTC
$0.00 +0.00% (+$0.00)
Market Cap $5.30K
P/E Ratio -
Div. Yield -
ROE -
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.02x
P/FCF N/A
P/FFO N/A
Growth
54 /100
Stable Rev. growth 6.92%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak FCF margin 1,000.14%
Op. margin 1,419.41%
Gross margin 320.09%
Quality
2 /100
Poor ROA 129.35%
Asset turnover 0.10x
ROIC 230.41%
Debt
52 /100
Moderate Int. coverage -5.51x
Net debt/EBITDA -0.46x
Current ratio 0.57x
Stability
43 /100
Moderate EPS volatility 30.33%
Profitable years 0
Beta 1.42x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CTABF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Richard C. Goldstein
Employees
-
Headquarters
Markham